Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2021.05.005 http://scihub22266oqcxt.onion/10.1016/j.cell.2021.05.005 34087172!8152891!34087172     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell 2021 ; 184 (12): 3086-3108 Nephropedia Template TP {{tp|p=34087172|t=2021. Tackling COVID-19 with neutralizing monoclonal antibodies |pdf=|usr=}}{{34087172}} gab.com Text Tackling COVID-19 with neutralizing monoclonal antibodies JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=34087172 #FOAvip Monoclonal antibodies (mAbs) have revolutionized the treatment of several human diseases, including cancer and autoimmunity and inflammatory conditions, and represent a new frontier for the treatment of infectious diseases. In the last 20 years, innovative methods have allowed the rapid isolation of mAbs from convalescent subjects, humanized mice, or libraries assembled in vitro and have proven that mAbs can be effective countermeasures against emerging pathogens. During the past year, an unprecedentedly large number of mAbs have been developed to fight coronavirus disease 2019 (COVID-19). Lessons learned from this pandemic will pave the way for the development of more mAb-based therapeutics for other infectious diseases. Here, we provide an overview of SARS-CoV-2-neutralizing mAbs, including their origin, specificity, structure, antiviral and immunological mechanisms of action, and resistance to circulating variants, as well as a snapshot of the clinical trials of approved or late-stage mAb therapeutics. Twit Text FOAVip Tackling COVID-19 with neutralizing monoclonal antibodies ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=34087172 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34087172 #FOAvip English Wikipedia <ref>{{Cite pmid|34087172}}</ref> Tackling COVID-19 with neutralizing monoclonal antibodies #MMPMID34087172 Corti D; Purcell LA; Snell G; Veesler D Cell 2021[Jun]; 184 (12): 3086-3108 PMID34087172show ga Monoclonal antibodies (mAbs) have revolutionized the treatment of several human diseases, including cancer and autoimmunity and inflammatory conditions, and represent a new frontier for the treatment of infectious diseases. In the last 20 years, innovative methods have allowed the rapid isolation of mAbs from convalescent subjects, humanized mice, or libraries assembled in vitro and have proven that mAbs can be effective countermeasures against emerging pathogens. During the past year, an unprecedentedly large number of mAbs have been developed to fight coronavirus disease 2019 (COVID-19). Lessons learned from this pandemic will pave the way for the development of more mAb-based therapeutics for other infectious diseases. Here, we provide an overview of SARS-CoV-2-neutralizing mAbs, including their origin, specificity, structure, antiviral and immunological mechanisms of action, and resistance to circulating variants, as well as a snapshot of the clinical trials of approved or late-stage mAb therapeutics. |Angiotensin-Converting Enzyme 2/chemistry/immunology/metabolism[MESH] |Animals[MESH] |Antibodies, Monoclonal/chemistry/*immunology/therapeutic use[MESH] |Antibodies, Neutralizing/chemistry/*immunology/therapeutic use[MESH] |Antibodies, Viral/chemistry/immunology/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/pathology/virology[MESH] |Humans[MESH] |SARS-CoV-2/*immunology/isolation & purification/metabolism[MESH]Tackling COVID-19 with neutralizing monoclonal antibodies (epmc).pdf DeepDyve Pubget Overpricing